CEBPA and acute myeloid leukemia: Mutations that reduce long isoform expression are frequently seen in acute myeloid leukemia (AML), including mutations in CEBPA itself that occur in 10–15% of these cancers (51, 56), emphasizing that the stoichiometry of these two isoforms must be maintained for proper differentiation.